Pirnabine is the synthetic dibenzopyran drug. It was developed as anti-glaucoma drug.

Pentisomicin (Sch 21420) is semisynthetic aminoglycosides with marked antibacterial activity. Like many new aminoglycosides prepared by chemical modification or mutational biosynthesis, Pentisomicin was designed either to enhance potency of the parent compound and/or resist enzymatic inactivation. The activity of Pentisomicin was comparable to gentamicin, sisomicin, netilmicin, and tobramycin but greater than amikacin or kanamycin against S. aureus and most genera of Enterobacteriaceae.

Pararosaniline pamoate (CI 403-A) was developed as an orally active drug for the treatment of Schistosoma japonicum infection. The clinical trial has shown that capsules were safe and effective; in addition, this drug was well tolerated with a minimum of side effects, which were mostly mild and transient and did not require interruption of treatment. Besides, pararosaniline pamoate was an inhibitor of E.histolytica Hsp90 (EhHsp90) with promising activity against the parasite Pararosaniline pamoate, that causes amebiasis worldwide. Information about the current use of this drug is not available.

Furcloprofen was developed as an analgesic agent with anti-inflammatory properties. Information about the current use of this compound is not available.

Thiazosulfone (also known as Promizole) is a phenylsulfonylthiazole derivative patented by Parke, Davis & Co. as the anti-tuberculosis agent. In preclinical models, Thiazosulfone exerts a definitely favorable influence on the course of experimental tuberculosis previously established in the highly susceptible guinea pig. In clinical trials Thiazosulfone and Streptomycin combined therapy exerts favor influences on tuberculous meningitis. Thiazosulfone seems to have an inhibitory action on hematogenous tuberculosis. Its toxicity is very low and it can, therefore, be administered for a prolonged period.

Pirinixic acid is a PPARα ligand that can affect atherogenesis by modulating hepatic lipid metabolism and by acting directly on vascular tissue. PPARα activation is generally assumed to be the primary means by which Pirinixic acid produces its biological effects. Nevertheless, there is increasing evidence to suggest that Pirinixic acid is also capable of affecting cellular processes directly. It is under experimental investigation for prevention of severe cardiac dysfunction, cardiomyopathy and heart failure as a result of lipid accumulation within cardiac myocytes. Treatment is primarily aimed at individuals with an adipose triglyceride lipase (ATGL) enzyme deficiency or mutation. For example, cardiac contractility was improved by treating ATGL(-/-) mice with the Pirinixic acid.

Duoperone is a neuroleptic agent. Duoperone blocked d-amphetamine lethality in mice under aggregated conditions when the pretreatment interval was between one hour and seven days. Conditioned avoidance responding in mice and cats was suppressed by duoperone in doses that did not impair escape behavior. Duoperone produced catalepsy in rats. The onset of this effect was delayed and the duration was prolonged when compared with that of chlorpromazine. It was a potent antiemetic agent in dogs, with a delayed onset and prolonged duration of action.

The BET-bromodomain inhibitor OTX015 (MK-8628) was initially developed by Mitsubishi Tanabe Pharma Corporation, but then was licensed by OncoEthix, privately held biotechnology company. OTX015 is a selective bromodomains: BRD2, BRD3, and BRD4 inhibitor and inhibits their binding to AcH4. Bromodomains have an important role in the targeting of chromatin-modifying enzymes to specific sites, including methyltransferases, HATs and transcription factors and regulate diverse biological processes from cell proliferation and differentiation to energy homeostasis and neurological processes. OTX015 has potent antiproliferative activity accompanied by c-MYC down-regulation in several tumor types, and has demonstrated synergism with the mTOR inhibitor everolimus in different models. Oral administration of OTX-015 markedly inhibited tumor growth and reduced tumor volume. OTX015 is currently in Phase 1b studies for the treatment of hematological malignancies and advanced solid tumors such as Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Castrate-resistant Prostate Cancer (CRPC) and Pancreatic Ductal Adenocarcinoma. In addition, OTX015 was in phase II for the treatment of Glioblastoma Multiforme, but there were not detected clinical activity of the drug in the treatment populations and trial was closed.

Dicarbine is an orally active drug approved in Russia under the trade name Карбидин, is used for the treatment patients with schizophrenia and alcoholic psychosis. This drug blocks dopamine receptors in various brain parts, which leads to a reduction in the productive symptoms of psychosis: delusions and hallucinations.

Tiazuril is a triazinedione derivative patented by American multinational pharmaceutical corporation Pfizer Inc. as the coccidiostatic agent. Tiazuril controlled all the major species of poultry coccidia at low concentrations but elicited toxicological symptoms suggesting interference with nucleic acid synthesis.